FDA Grants Fast-Track Designation for Phenoxodiol in Oral Dosage Form
The FDA has granted Marshall Edwards' investigational anticancer drug, phenoxodiol, fast-track status for its intended use in patients with hormone-refractory prostate cancer (HRPC).
300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.
Copyright by FDAnews. All rights reserved. Do not duplicate or redistribute in any form.